WIRED put the latest consumer exoskeletons from Dnsys and Hypershell in a head-to-head test on a pro athletic track. On your ...
By Mariam Sunny Jan 26 (Reuters) - Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy slowed disease ...
TL;DRIn addition to my two Ventos, an Octavia 1.4 TSI MT also calls my garage its home now. I test drove a Kizashi, i20 ...
Closed for nearly three years for renovations, the Shanghai Science and Technology Museum, which has undergone an 820 million ...
With all the automation in today’s manufacturing plants, the typical maintenance technician with a few years or more of ...
Shah Rukh Khan leads nostalgic brand film; UGC contest, ICC-themed displays, dealership activations and stadium experiences ...
The new year has not started well for China, with two failures among its first six launches. Even so, 2026 is shaping up to ...
In the same week in November 2025, Kia unveiled the all-new 2027 Telluride and Honda announced the comprehensively updated 2026 Pilot. Both are three-row crossovers, but the Honda is at a more ...
HANGZHOU, ZHEJIANG PROVINCE, CHINA, January 16, 2026 /EINPresswire.com/ -- The wedding furniture manufacturing sector ...
WANTI PLAZA, YIWU CITY, ZHEJIANG PROVINCE, CHINA, January 16, 2026 /EINPresswire.com/ -- The global toy manufacturing ...
InvestorsHub on MSN
Sarepta posts encouraging three-year data for Duchenne gene therapy
Sarepta Therapeutics Inc. (NASDAQ:SRPT) released three-year follow-up results from its EMBARK study, showing that its gene ...
Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy January 26, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results